DK1199368T3 - Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse - Google Patents

Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse

Info

Publication number
DK1199368T3
DK1199368T3 DK01124236T DK01124236T DK1199368T3 DK 1199368 T3 DK1199368 T3 DK 1199368T3 DK 01124236 T DK01124236 T DK 01124236T DK 01124236 T DK01124236 T DK 01124236T DK 1199368 T3 DK1199368 T3 DK 1199368T3
Authority
DK
Denmark
Prior art keywords
expression
gene
interest
adenovirus
reading frames
Prior art date
Application number
DK01124236T
Other languages
Danish (da)
English (en)
Inventor
Monika Lusky
Majid Mehtali
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1199368T3 publication Critical patent/DK1199368T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
DK01124236T 1998-07-07 1999-07-01 Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse DK1199368T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401722 1998-07-07
EP98402825 1998-11-13

Publications (1)

Publication Number Publication Date
DK1199368T3 true DK1199368T3 (da) 2004-04-13

Family

ID=26151663

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01124236T DK1199368T3 (da) 1998-07-07 1999-07-01 Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse
DK99401645T DK0974668T3 (da) 1998-07-07 1999-07-01 Anvendelse af E4-læserammer fra adenovirus til forbedring af ekspression af et gen af interesse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99401645T DK0974668T3 (da) 1998-07-07 1999-07-01 Anvendelse af E4-læserammer fra adenovirus til forbedring af ekspression af et gen af interesse

Country Status (11)

Country Link
US (1) US6475480B1 (fr)
EP (2) EP1199368B1 (fr)
JP (1) JP2000106875A (fr)
AT (2) ATE258228T1 (fr)
AU (1) AU756607B2 (fr)
CA (1) CA2276791A1 (fr)
DE (2) DE69914382T2 (fr)
DK (2) DK1199368T3 (fr)
ES (2) ES2210081T3 (fr)
HK (1) HK1043390A1 (fr)
PT (2) PT974668E (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225113B1 (en) * 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
JP2003534806A (ja) * 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
EP1203819A3 (fr) * 2000-10-06 2002-08-07 Transgene S.A. Vecteurs anti-inflammatoires
EP1539937A4 (fr) * 2002-08-22 2006-07-26 Merck & Co Inc Methodes de propagation d'adenovirus et virus ainsi obtenu
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
WO2006070023A2 (fr) * 2004-12-31 2006-07-06 Per Sonne Holm Methode d'annulation de la multiresistance dans des cellules animales
US20080166322A1 (en) * 2006-12-08 2008-07-10 Atkinson Richard L Methods for producing an adenovirus type 5 gene transfer vector
WO2008089448A2 (fr) * 2007-01-19 2008-07-24 Cornell Presearch Foundation, Inc. Procédés et compositions pour la favorisation de la survie et de la prolifération de cellules endothéliales et la stimulation d'angiogenèse
BR112013003579A2 (pt) 2010-08-16 2016-06-07 Salk Inst For Biological Studi adenovírus, células, e, métodos para tratar câncer
KR101522341B1 (ko) * 2012-10-02 2015-05-21 국립암센터 신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
EP3587455A1 (fr) 2012-10-23 2020-01-01 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
CA2903582C (fr) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Compositions d'adenovirus oncolytiques
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
EP4155411A1 (fr) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Expression d'un gène exogene d'un adenovirus therapeutique avec impact minimaire sur la cinetique virale
JP7078620B2 (ja) 2016-11-16 2022-05-31 イミュノミック セラピューティックス， インコーポレイテッド アレルギーの治療のための核酸
WO2018111767A1 (fr) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Adénovirus synthétiques ciblant une tumeur et leurs utilisations
CA3061950A1 (fr) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Constructions de lamp (proteine membranaire associee au lysosome) comprenant des antigenes cancereux
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
CA3100004A1 (fr) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Constructions ameliorees de lamp comprenant des allergenes
CN114072516A (zh) * 2019-05-30 2022-02-18 磨石生物公司 经修饰的腺病毒
CN114641306A (zh) 2019-10-18 2022-06-17 免疫治疗有限公司 包含癌抗原的改良lamp构建物
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
CN110656090B (zh) * 2019-10-28 2023-06-30 嘉兴安宇生物科技有限公司 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
WO2022007800A1 (fr) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 Vaccin adénoviral recombinant pour la peste porcine africaine et procédé pour le construire
EP4242318A4 (fr) 2021-01-21 2024-02-14 Cellid Co., Ltd Nouveau vecteur adénoviral ne comprenant pas d'adénovirus compétent de réplication et utilisation associée
AU2023254186A1 (en) 2022-04-10 2024-10-17 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
CA2145641C (fr) * 1992-12-03 2008-05-27 Richard J. Gregory Vecteurs pseudo-adenoviraux
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6110744A (en) * 1996-11-13 2000-08-29 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence

Also Published As

Publication number Publication date
AU3800999A (en) 2000-06-08
HK1043390A1 (zh) 2002-09-13
ES2210081T3 (es) 2004-07-01
DE69914382D1 (de) 2004-02-26
EP1199368A2 (fr) 2002-04-24
DE69903229T2 (de) 2003-06-26
DE69914382T2 (de) 2004-11-04
EP1199368A3 (fr) 2002-07-17
PT1199368E (pt) 2004-04-30
DK0974668T3 (da) 2002-11-11
ATE225400T1 (de) 2002-10-15
US6475480B1 (en) 2002-11-05
PT974668E (pt) 2003-01-31
ES2180258T3 (es) 2003-02-01
DE69903229D1 (de) 2002-11-07
EP1199368B1 (fr) 2004-01-21
CA2276791A1 (fr) 2000-01-07
EP0974668B1 (fr) 2002-10-02
ATE258228T1 (de) 2004-02-15
AU756607B2 (en) 2003-01-16
JP2000106875A (ja) 2000-04-18
EP0974668A1 (fr) 2000-01-26

Similar Documents

Publication Publication Date Title
DK1199368T3 (da) Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse
IL234063A (en) Adenovirus containing capsid aavrh.34 and a heterologous gene, its preparation and preparations containing it
WO2005001103A3 (fr) Procede pour produire des adenovirus chimeriques et utilisations de ces derniers
Colby et al. Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX
IL199127A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters
DK1127150T3 (da) Nucleinsyresekvenser fra det adeno-associerede virus af serotype 1 samt vektorer og værtsceller, der indeholder disse
AU2002359284A8 (en) Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
PT2359869T (pt) Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
HK1071518A1 (en) Improved raav expression systems for genetic modification of specific capsid proteins
AUPN477695A0 (en) Gene therapy
WO2006116267A3 (fr) Molecule a specificite cellulaire, et procede pour introduire de l'adn dans des noyaux d'osteoblaste
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
HU9600668D0 (en) Grb3-3 gene, variants and uses thereof
WO2005010149A3 (fr) Vecteurs adenoviraux du sous-groupe b pour le traitement de maladies
IL94053A0 (en) Methods and nucleic acid sequences for the expression of the cellulose synthase operon
WO2006086357A3 (fr) Vecteurs adenoviraux de serotype 36, acides nucleiques et virus ainsi produits
WO1992014818A3 (fr) Systeme d'expression d'entomopoxvirus comprenant des sequences de spheroïdine ou de thymidine-kinase
WO2003031633A3 (fr) Systeme vecteur adenoviral
TH78124B (th) วัคซีนหน่วยย่อย ns1 ของเฟลวิไวรัส
TH62970A (th) วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)